Related Experiment Video
Updated: Jun 1, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
What are the different initial presentations of frontotemporal dementia?
1Department of Medicine, Division of Neurology, University of Toronto, Rotman Research Institute, 3560 Bathurst St, Toronto, ON, M6A 2E1, Canada. tchow@rotman-baycrest.on.ca
Journal of Molecular Neuroscience : MN
|May 28, 2011
Summary
Frontotemporal dementia (FTD) presents with behavioral changes or aphasia. Identifying the specific protein abnormality (tau, TDP-43, or FUS) aids in predicting disease progression and guiding personalized treatments.
Area of Science:
- Neuroscience
- Neurology
- Genetics
Background:
- Frontotemporal dementia (FTD) is a neurodegenerative disorder.
- Early symptoms manifest as behavioral disturbances or language impairments (aphasia).
- Specific proteinopathies, including tau, TDP-43, and FUS, are implicated in FTD.
Purpose of the Study:
- To correlate early FTD symptoms with specific underlying protein abnormalities.
- To explore the utility of family history in diagnosing FTD subtypes.
- To inform prognosis and clinical trial eligibility based on proteinopathy identification.
Main Methods:
- Clinical symptom assessment (behavioral changes, aphasia characteristics).
- Analysis of family history for recurrent FTD cases.
- Biomarker identification for common FTD proteinopathies (tau, TDP-43, FUS).
Main Results:
- Distinct symptom clusters correlate with specific FTD proteinopathies.
- Family history can suggest a genetic predisposition and guide diagnosis.
- Accurate proteinopathy identification is crucial for patient management.
Conclusions:
- Early symptom presentation in FTD can predict the underlying proteinopathy.
- Integrating clinical, familial, and molecular data enhances diagnostic accuracy.
- Understanding proteinopathy is key for personalized FTD care and targeted therapies.
Related Concept Videos
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...